Skye Bioscience (SKYE) focuses on developing proprietary molecules to treat diseases involving inflammatory, fibrotic, and metabolic conditions. CEO Punit Dhillon joins Nicole Petallides to discuss the latest in drug development. He also talks about the competition in the obesity space. Tune in to find out more about the stock market today.
Trading 360
14 May 2024
SHARE